Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Sep 15;124(18):3638-3640.
doi: 10.1002/cncr.31627. Epub 2018 Jul 5.

Toxicities and outcomes: Do steroids matter?

Douglas B Johnson  1
Affiliations
Editorial

Toxicities and outcomes: Do steroids matter?

Douglas B Johnson. Cancer. .

Abstract

Hypophysitis is a common toxicity of ipilimumab and may be managed with either low- or high-dose steroids. In this issue of Cancer, Faje and colleagues observe that patients treated with low-dose steroids have equivalent rates of hypophysitis resolution compared to those who receive higher doses. Importantly, however, melanoma-specific outcomes are improved in the low-dose cohort. Herein, we discuss the implications of this finding and the known associations between steroids and clinical outcomes to cancer immunotherapy.

PubMed Disclaimer

Comment on

References

    1. Wolchok JD. PD-1 Blockers. Cell. 2015;162:937. - PubMed
    1. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378:158–168. - PubMed
    1. Wang DY, Johnson DB, Davis EJ. Toxicities Associated With PD-1/PD-L1 Blockade. Cancer J. 2018;24:36–40. - PMC - PubMed
    1. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005;353:1711–1723. - PubMed
    1. Horvat TZ, Adel NG, Dang TO, et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193–3198. - PMC - PubMed